

APOL1 and Proteinuria in the AASK

Unraveling the Pathobiology of APOL1

John F. O'Toole, Leslie A. Bruggeman, and John R. Sedor

Clin J Am Soc Nephrol 12: 1723–1725, 2017. doi: <https://doi.org/10.2215/CJN.10680917>

Nucleic acid variants in the sequence of the gene for *APOL1*, which change the amino acid sequence, strongly associate with nondiabetic kidney diseases only in blacks (1). *APOL1* risk genotype-associated kidney disease phenotypes in blacks include hypertension-associated kidney disease, FSGS, HIV-associated nephropathy (HIVAN), and other diseases, which span standard pathologic classifications, and additional clinical (e.g., eGFR decline) and histopathologic phenotypes. Unlike almost all other common disease-associated polymorphisms, *APOL1* kidney disease-associated variants have large effect sizes. Given this, defining the biology responsible for the genetic association could identify novel, high-effect treatment targets for a major health disparity.

APOL1 is an innate immune effector protein that causes trypanolysis (1). However, two trypanosome subspecies evolved mechanisms to block *APOL1*'s trypanolytic activity, permitting transmission of African sleeping sickness. The *APOL1* proteins encoded by the kidney disease-associated variants restore trypanolytic activity against one of the subspecies. Analogous to the link between the hemoglobin mutation that confers protection from malaria but also causes sickle cell disease, a single copy of a variant *APOL1* allele protects the carrier from sleeping sickness, but two copies confer increased risk for kidney diseases. Driven by positive selection in sub-Saharan Africa, because variant *APOL1*s confer resistance to sleeping sickness, the *APOL1*-associated kidney disease risk genotype is common. From 12% to 15% of black individuals carry the risk genotype (i.e., two *APOL1* kidney disease risk alleles). Fortunately, most individuals with the *APOL1* risk genotype do not develop kidney diseases, suggesting that a second stressor is needed to initiate disease. Genetic association studies have identified the only known environmental trigger: uncontrolled HIV infection. Without antiretroviral therapy, individuals with the *APOL1* risk genotype have a 50% lifetime risk of developing HIVAN.

In contrast, most blacks who are hypertensive with high-risk *APOL1* genotypes do not develop CKD, suggesting that high BP accelerates kidney disease progression but does not initiate kidney disease. The African American Study of Kidney Disease and Hypertension (AASK) cohort has been studied to characterize associations of *APOL1* variants with clinical phenotypes in subjects with CKD and high BP. At

entry, the AASK participants had CKD (measured GFR between 20 and 65 ml/min per 1.73 m²) attributed to hypertension and <2 g proteinuria. Prevalent proteinuria is more common at baseline in the AASK subjects with high-risk *APOL1* genotypes compared with those with low-risk *APOL1* genotypes (48% versus 25%; $P < 0.001$) (2). In this issue of the *Clinical Journal of the American Society of Nephrology*, Chen *et al.* (3) asked if incident proteinuria differed in the AASK subjects with and without high-risk *APOL1* genotypes. The study included 480 of the original 1094 AASK participants: 362 with prevalent or unknown proteinuria at study entry and 252 without *APOL1* genotypes were excluded. In aggregate, 53% ($n = 254$) of this study population developed proteinuria during a median follow-up of nearly 7 years. Incident proteinuria was more frequent in individuals with high-risk *APOL1* genotypes (56 of 82 participants) compared with those with the low-risk genotypes (198 of 398 participants; hazard ratio, 1.82; 95% confidence interval [95% CI], 1.35 to 2.46; $P < 0.01$). Excluded subjects with prevalent proteinuria were younger, had a lower eGFR, and had a higher frequency of high-risk *APOL1* genotypes, suggesting that the excluded AASK subjects had more advanced or severe CKD than subjects included in this analysis. The effect size of *APOL1* high-risk genotypes on proteinuria may have been underestimated by an analytic design that required that these participants be excluded.

When all AASK participants with *APOL1* genotypes ($n = 693$) were analyzed, those with high-risk genotypes more commonly reached the composite kidney outcome (an eGFR decline >50% from baseline or ESRD) (2). Chen *et al.* (3) also found a faster eGFR decline in subjects without proteinuria at study entry but with high- compared with low-risk *APOL1* genotypes (−1.65; 95% CI, −2.05 to −1.25 versus −1.11; 95% CI, −1.32 to −0.90; P interaction = 0.01). Interestingly, the rate of eGFR decline before and after proteinuria onset was independent of *APOL1* genotype risk status. Therefore, the overall faster rate of eGFR decline in these AASK participants with *APOL1* high-risk genotypes reflects the increased frequency of proteinuria in this group compared with participants with low-risk genotypes. Previously, an association between high-risk *APOL1* genotypes and ESRD in an unadjusted analysis was lost after adjustment for proteinuria (4). Somewhat surprisingly, these data, in aggregate,

Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute and Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio

Correspondence:

Dr. John R. Sedor, Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, 2050 East 96th Street, Cleveland, OH 44195. Email: seedorj@ccf.org

suggest proteinuria, after it is established, is the dominant risk for adverse kidney disease outcomes, regardless of *APOL1* risk genotype status.

How does the study of the AASK participants by Chen *et al.* (3) inform hypotheses about mechanisms of *APOL1*-associated kidney diseases? Proteinuria reflects glomerular filtration barrier dysfunction. Podocytes are key components of the glomerular filtration barrier, and *APOL1* is abundantly expressed within podocytes of healthy kidney (5). Emerging data describing *APOL1* effects on podocyte biology may explain the increased frequency of prevalent and incident proteinuria in blacks with high-risk *APOL1* genotypes. *APOL1* is a human-only gene, but several transgenic animal models have been published. Similar to humans, mice with podocyte-restricted expression of a reference or variant *APOL1* transgene lack markers of cell death or do not have overt kidney disease, even after 300 days of observation (6). Despite the absence of “clinical” kidney disease, mice expressing a variant *APOL1* transgene have reduced podocyte density compared with age-matched reference *APOL1* transgenic mice. As proposed by the podocyte depletion hypothesis, this reduced podocyte reserve may predispose to overt kidney disease development when a stress is superimposed (7). Similar results were published in zebrafish with podocyte-specific transgenic expression of a variant *APOL1* transgene (8). Podocytes had ultrastructural evidence of injury, but the fish had no overt kidney disease phenotypes. In contrast, mice with inducible reference or variant *APOL1* transgene expression and fruit flies expressing reference and variant *APOL1* transgenes showed variant-dependent podocyte death and filtration barrier dysfunction (9–11). Like the mice with constitutive expression of a variant *APOL1* transgene, the transgenic flies and mice with inducible, variant *APOL1* transgenes have fewer nephrocytes (podocyte-like cells in the fly) or podocytes, respectively. In aggregate, variant *APOL1* seems to cause podocyte depletion by either cytotoxicity or alternatively, podocyte detachment (the mice with constitutive variant *APOL1* expression had fewer podocytes but no cell death). Interestingly, soluble urokinase plasminogen receptor, a circulating biomarker that predicts kidney disease incidence and progression, interacts with variant but not reference *APOL1* to activate a podocyte integrin adhesion molecule and cause podocyte detachment in culture and soluble urokinase plasminogen receptor–dependent proteinuria in mice (12).

Another common feature of these different animal models is the dysregulation of intracellular trafficking of membrane-bound vesicles. Marilyn Farquhar and colleagues noted 60 years ago the abundance of vesicles within the podocyte, a finding confirmed in subsequent studies of normal and diseased podocytes (13). Deletion of a protein regulator of vesicular trafficking resulted in an FSGS-like phenotype in mice, emphasizing the importance of trafficking pathways for podocyte homeostasis (14). Linking *APOL1* function with vesicular trafficking, reference but not variant *APOL1*s interact with a vesicle-associated membrane protein (15). More work is needed to dissect the pathways responsible for podocyte depletion and identify better CKD treatments.

From human data, we know that *APOL1* function is not required for normal filtration barrier function, that *APOL1* is an innate immune effector protein, and that a “second hit” is required for kidney disease to ensue in subjects with the

APOL1 risk genotype, such as an uncontrolled HIV infection in HIVAN. Integrating these observations with the experimental data described above, we propose that *APOL1* is not required for normal kidney function but rather, samples the ambient environment by interacting with vesicles trafficking through the podocyte. When a disease-causing stress is sensed, reference *APOL1* detects and contains environmental danger signals carried by vesicles. Variant *APOL1* proteins fail to do so, permitting glomerular filtration barrier dysfunction. Of course, *APOL1*-independent pathways may also lead to proteinuria, and as shown in the study by Chen *et al.* (3), progressive kidney function loss ensues no matter the patient’s *APOL1* genotype.

What are the next steps to translate a groundbreaking discovery, the association of *APOL1* variants with non-diabetic kidney diseases, to the clinic? Certainly, better models are needed to define mechanisms of *APOL1*-dependent kidney diseases. Few, if any, studies have analyzed *APOL1* function in cells or animals exposed to a stress. Exploiting the strong genetic association between HIV-associated kidney disease and the *APOL1* kidney disease risk variants is a plausible approach to implement. Hypertensive-associated kidney disease most likely represents a number of molecular mechanisms that generate similar clinical findings and kidney histopathology. To more effectively manage and treat this inexorable disease, we need kidney tissue to better characterize the *APOL1*-dependent and -independent molecular pathways responsible for hypertensive-associated kidney disease in blacks. The Kidney Precision Medicine Project provides an unprecedented opportunity to accomplish this goal (16). This study will use omics tools to produce molecular phenotypes from kidney biopsies and then integrate these data with histopathology phenotypes generated by computational methods and longitudinal clinical data abstracted from electronic health records. Population health is the latest mantra, often chanted uncritically, for innovative health care delivery models, but it will fail unless precision medicine defines the populations.

Acknowledgments

The authors are supported by National Institutes of Health grants DK097836, DK108329, DK083912, DK100846, and DK114908 and funds from the Kidney Foundation of Ohio.

Disclosures

The authors have received consultancy and royalty fees from Sanofi-Genzyme.

References

1. Friedman DJ, Pollak MR: Apolipoprotein L1 and kidney disease in African Americans. *Trends Endocrinol Metab* 27: 204–215, 2016
2. Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT Jr., Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ: AASK Study Investigators; CRIC Study Investigators: *APOL1* risk variants, race, and progression of chronic kidney disease. *N Engl J Med* 369: 2183–2196, 2013
3. Chen T, Tin A, et al: *APOL1* risk variants, incident proteinuria, and subsequent eGFR decline in African Americans with hypertension-attributed chronic kidney disease. *Clin J Am Soc Nephrol* 12: 1771–1777, 2017
4. Grams ME, Li L, Greene TH, Tin A, Sang Y, Kao WH, Lipkowitz MS, Wright JT, Chang AR, Astor BC, Appel LJ: Estimating time to ESRD

- using kidney failure risk equations: Results from the African American Study of Kidney Disease and Hypertension (AASK). *Am J Kidney Dis* 65: 394–402, 2015
5. Madhavan SM, O'Toole JF, Konieczkowski M, Ganesan S, Bruggeman LA, Sedor JR: APOL1 localization in normal kidney and nondiabetic kidney disease. *J Am Soc Nephrol* 22: 2119–2128, 2011
 6. Bruggeman LA, Wu Z, Luo L, Madhavan SM, Konieczkowski M, Drawz PE, Thomas DB, Barisoni L, Sedor JR, O'Toole JF: APOL1-G0 or APOL1-G2 transgenic models develop preeclampsia but not kidney disease. *J Am Soc Nephrol* 27: 3600–3610, 2016
 7. Kikuchi M, Wickman L, Hodgins JB, Wiggins RC: Podometrics as a potential clinical tool for glomerular disease management. *Semin Nephrol* 35: 245–255, 2015
 8. Olabisi O, Al-Romaih K, Henderson J, Tomar R, Drummond I, MacRae C, Pollak M: From man to fish: What can Zebrafish tell us about ApoL1 nephropathy? *Clin Nephrol* 86: 114–118, 2016
 9. Beckerman P, Bi-Karchin J, Park AS, Qiu C, Dummer PD, Soomro I, Boustany-Kari CM, Pullen SS, Miner JH, Hu CA, Rohacs T, Inoue K, Ishibe S, Saleem MA, Palmer MB, Cuervo AM, Kopp JB, Susztak K: Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. *Nat Med* 23: 429–438, 2017
 10. Kruzel-Davila E, Shemer R, Ofir A, Bavli-Kertseli I, Darlyuk-Saadon I, Oren-Giladi P, Wasser WG, Magen D, Zaknoun E, Schuldiner M, Salzberg A, Kornitzer D, Marelja Z, Simons M, Skorecki K: APOL1-mediated cell injury involves disruption of conserved trafficking processes. *J Am Soc Nephrol* 28: 1117–1130, 2017
 11. Fu Y, Zhu JY, Richman A, Zhang Y, Xie X, Das JR, Li J, Ray PE, Han Z: APOL1-G1 in nephrocytes induces hypertrophy and accelerates cell death. *J Am Soc Nephrol* 28: 1106–1116, 2017
 12. Hayek SS, Koh KH, Grams ME, Wei C, Ko YA, Li J, Samelko B, Lee H, Dande RR, Lee HW, Hahm E, Peev V, Tracy M, Tardi NJ, Gupta V, Altintas MM, Garborcauskas G, Stojanovic N, Winkler CA, Lipkowitz MS, Tin A, Inker LA, Levey AS, Zeier M, Freedman BI, Kopp JB, Skorecki K, Coresh J, Quyyumi AA, Sever S, Reiser J: A tripartite complex of suPAR, APOL1 risk variants and $\alpha\text{v}\beta\text{3}$ integrin on podocytes mediates chronic kidney disease. *Nat Med* 23: 945–953, 2017
 13. Farquhar MG, Wissig SL, Palade GE: Glomerular permeability. I. Ferritin transfer across the normal glomerular capillary wall. *J Exp Med* 113: 47–66, 1961
 14. Bechtel W, Helmstädter M, Balica J, Hartleben B, Kiefer B, Hrnjic F, Schell C, Kretz O, Liu S, Geist F, Kerjaschki D, Walz G, Huber TB: Vps34 deficiency reveals the importance of endocytosis for podocyte homeostasis. *J Am Soc Nephrol* 24: 727–743, 2013
 15. Madhavan SM, O'Toole JF, Konieczkowski M, Barisoni L, Thomas DB, Ganesan S, Bruggeman LA, Buck M, Sedor JR: APOL1 variants change C-terminal conformational dynamics and binding to SNARE protein VAMP8. *JCI Insight* 2: 92581, 2017
 16. Norton JM, Ketchum CJ, Narva AS, Star RA, Rodgers GP: Complementary initiatives from the NIDDK to advance kidney health. *Clin J Am Soc Nephrol* 12: 1544–1547, 2017

Published online ahead of print. Publication date available at www.cjasn.org.

See related article, “APOL1 Risk Variants, Incident Proteinuria, and Subsequent eGFR Decline in Blacks with Hypertension-Attributed CKD,” on pages 1771–1777.